NCT00760448已完成1 期
Trial Investigating the Hypoglycaemic Response to Single Doses of Insulin Detemir and NPH Insulin in Subjects With Type 1 Diabetes
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 2
- 主要终点
- Baseline-adjusted hypoglycaemic symptoms score at nadir plasma glucose concentration based on the Edinburgh Hypoglycaemia Scale: autonomic symptoms, neuroglycopenic symptoms and general malaise
研究概览
简要总结
This trial is conducted in UK. The aim of this clinical trial is to investigate lowering the blood sugar and symptoms experienced during hypoglycaemia
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated informed consent obtained before any trial-related activities.
- •Type 1 diabetes
- •Treatment with insulin for minimum three months
- •Duration of diabetes for more than 12 months
- •Body Mass Index (BMI) less than 30 kg/m2
- •HbA1c equal to or greater than 10 % based on analysis from central laboratory
排除标准
- •Participation in any other clinical trial involving other investigational products within the last three months
- •Current treatment with insulin in a daily dose above 100 U
- •Episode of symptomatic hypoglycaemia, or a capillary plasma glucose value of less than 3.5 mmol/L in the past two weeks
- •Hypoglycaemic unawareness or severe autonomic neuropathy
- •Current treatment with drugs known to interfere with glucose metabolism such as systemic corticosteroids, non-selective beta-blockers and MAO inhibitors
- •Current treatment with oral antidiabetic drugs
- •Impaired hepatic function measured as ALAT of more than two times the upper reference limit
- •Impaired renal function measured as creatinine of more than 150 micromol/L (1.7 mg/dL)
- •Cardiac problems defined as decompensated heart failure (NYHA class III and IV) at any time and/or angina pectoris and/or myocardial infarction within the last 12 months
- •Known or suspected allergy to trial product or related products
- •Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation
- •Blood donation of more than 500 mL within the last three months
- •Any condition that the Investigator and/or the Sponsor feels would interfere with study participation or evaluation of results
- •Pregnancy or intention of becoming pregnant, breast-feeding or judged to be using inadequate contraceptive methods. Adequate contraceptive methods are sterilisation, intrauterine device (IUD), oral contraceptives or consistent use of barrier methods
- •Previous participation in this trial
结局指标
主要结局
Baseline-adjusted hypoglycaemic symptoms score at nadir plasma glucose concentration based on the Edinburgh Hypoglycaemia Scale: autonomic symptoms, neuroglycopenic symptoms and general malaise
时间窗: From -40 min and until immediately before trial product administration
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 DiabeticsDiabetesDiabetes Mellitus, Type 1NCT01002768Novo Nordisk A/S28
已完成
1 期
A Trial Investigating the Effect of NN5401 in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01134224Novo Nordisk A/S39
已完成
1 期
A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 DiabeticsDiabetesDiabetes Mellitus, Type 1NCT00964964Novo Nordisk A/S18
已完成
1 期
A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 DiabeticsDiabetes Mellitus, Type 2NCT01147861GlaxoSmithKline39
已完成
1 期
A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1NCT00964418Novo Nordisk A/S27